UAB part of study of new drug for vasculitisUAB NewsWhile standard therapy consists of daily oral doses of a cancer drug called cyclophosphamide, followed by azathioprine, an immunosuppressant often used in organ transplant, researchers showed that fou…
Maintenance Rituximab in Advanced Follicular LymphomaCancer NetworkMaintenance therapy with rituximab(Drug information on rituximab) showed some improvement over observation, though it did not reach significance, among older patients with advanced foll…
|
BIOCAD Company and KOÇAK FARMA Sign a Definitive Agreement on Rituximab
Healthcare Global A Definitive Agreement on export of rituximab API produced by CJSC BIOCAD to Turkey was signed on August 13th, 2013 between CJSC BIOCAD and KOÇAK FARMA, a leading Turkish pharmaceutical company with strong presence in the area of oncology. |
|
BIOCAD Company and KOÇAK FARMA Sign a Definitive Agreement on Rituximab
PR.com (press release) A Definitive Agreement on export of rituximab API produced by CJSC BIOCAD to Turkey was signed on August 13th, 2013 between CJSC BIOCAD and KOÇAK FARMA, a leading Turkish pharmaceutical company with strong presence in the area of oncology. |
Emergent Biosolutions Inc (EBS): Emergent Biosciences Finally Expanding …Seeking AlphaThe anti-CD37 monoclonal antibody is in a Phase 2 combination study with Bendamustine in relapsed CLL patients. Otlertuzumab is also in a Phase 1b frontline CLL tri…
|
Biocad enters deal for exporting rituximab biosimilar to Turkey
The Pharma Letter Biocad, one of Russia’s leading biotechnology companies, has signed a definitive agreement on the export of rituximab active pharmaceutical ingredients (APIs) produced by the company with Kocak Farma, a leading Turkish drugmaker with strong presence … |
MD Arrested for Allegedly Unnecessary Cancer Treatment, a Hot New Risk AreaAtlantic Information Services, Inc.Patients were kept on the drug Rituximab for idiopathic thrombocytopenic purpura, a low-platelet condition. The affidavit says the drug is int…
Business Standard |
Dr Reddy’s, Intas to tap India’s Herceptin market
Business Standard DRL, the first company to launch a monoclonal antibody biosimilar in India, had launched Reditux (Rituximab) used in the treatment of Non-Hodgkin’s lymphoma (a kind of blood cancer) in 2007. On plans of launching Herceptin biosimilar, a DRL … |
|
The whys and hows of rituximab in thyroid eye disease
ModernMedicine “Immunobiologic agents are used early in patients with thyroid eye disease,” said Simeon Lauer, MD, clinical associate professor, Albert Einstein College of Medicine, Bronx, NY. “In most cases when an immunologic agent is thought to be needed, it is not. |
|
Cell Therapeutics’ Pixuvri gets French marketing nod to treat aggressive B …
pharmabiz.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have … |